Source: BioPortfolio

OBT: WuXi Biologics Announces $450 Million Bispecific Deal with Oxford BioTherapeutics

WuXi Biologics formed a $450 million partnership with England's Oxford BioTherapeutics to develop five novel bispecific antibodies including a PDL1 molecule using its WuXiBody Platform. OBT says the bispecifics will combine two secondgen immunon...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Christian Rohlff's photo - Founder & CEO of OBT

Founder & CEO

Christian Rohlff

CEO Approval Rating

86/100

OBT is a biotechnology company that focuses on the discovery and development of therapeutics for the treatment of cancer. Read more